Dianthus Therapeutics (DNTH) Equity Average: 2018-2025
Historic Equity Average for Dianthus Therapeutics (DNTH) over the last 6 years, with Sep 2025 value amounting to $424.8 million.
- Dianthus Therapeutics' Equity Average rose 22.04% to $424.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $424.8 million, marking a year-over-year increase of 22.04%. This contributed to the annual value of $260.7 million for FY2024, which is 318.75% up from last year.
- Dianthus Therapeutics' Equity Average amounted to $424.8 million in Q3 2025, which was up 34.49% from $315.8 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Equity Average registered a high of $424.8 million during Q3 2025, and its lowest value of -$56.1 million during Q2 2023.
- Moreover, its 3-year median value for Equity Average was $315.8 million (2025), whereas its average is $230.8 million.
- Its Equity Average has fluctuated over the past 5 years, first tumbled by 139.14% in 2023, then skyrocketed by 750.97% in 2024.
- Quarterly analysis of 4 years shows Dianthus Therapeutics' Equity Average stood at -$39.6 million in 2022, then soared by 538.88% to $173.6 million in 2023, then surged by 98.81% to $345.2 million in 2024, then climbed by 22.04% to $424.8 million in 2025.
- Its Equity Average was $424.8 million in Q3 2025, compared to $315.8 million in Q2 2025 and $340.5 million in Q1 2025.